A Long-term, Follow-up of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Novel HPV Vaccine in Healthy Female Subjects Vaccinated in the Primary Study

Inclusion Criteria:

- A female who enrolled in the study 102115 and received three doses of vaccine.

- Written informed consent obtained from the subject prior to enrolment.

Exclusion Criteria:

- Use (or planned use during the study period) of any investigational or non-registered
product or off-label use of licensed product (drug or vaccine).

- Chronic administration of immunosuppressants or other immune-modifying drugs
occurring less than three months prior to blood sampling.

- Administration of immunoglobulins and/or any blood products within the three months
preceding blood sampling.

- Planned administration of any HPV vaccine, other than that foreseen by the study
protocol, during the study period.